Xencor, Inc. (XNCR) Stock Price & Analysis

Xencor, Inc. (XNCR) closed at USD 29.21 on Thursday, October 29, 2026, down 2.60% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 29.99; the Oct 29, 2026 session ranged USD 28.92–30.56 on volume of 930,369 shares. Market capitalization is $2.17B, with a 52-week range of USD 10.38–33.6 (NGM). Source: Nexqual, retrieved October 29, 2026 at 20:49 UTC.

Also available as compact Markdown for AI agents: nexqual.com/XNCR.md

Key facts (XNCR)

• Last four reported quarters (through Jun 30, 2026): revenue $105M, net income -$163M (-155.6% margin), free cash flow -$208M (SEC filings).
• Insider open-market sales, last ~7 months: 6 Form 4 filings, $422K; 1 not under a Rule 10b5-1 plan ($43K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.93 on a 1–5 scale) (14 analysts), mean target USD 40.25 (range 21–70).
• Total return with dividends: 1Y +106.7% vs S&P 500 +14.4%; 5Y -26.2% vs S&P 500 +79.1%.
• Next earnings: 2026-11-04, EPS estimate USD -0.34, revenue estimate $63.0M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (XNCR)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (XNCR)

P/S 20.7x · EV/Sales 18.1x · P/B 4.3x · FCF yield -9.59% · Earnings yield -7.52% · Net cash $273M · EV $1.90B

Insider sales (SEC Form 4, open-market, last ~7 months) (XNCR)

5 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (XNCR)

Consensus Buy (mean 1.93 on a 1–5 scale), 14 analysts; mean target USD 40.25 (low 21, high 70).

Rating changes, last 120 days:

Total return (dividends reinvested) (XNCR)

XNCR earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

XNCR recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

XNCR revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

XNCR suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

Companies that name XNCR in their SEC reports

XNCR company outlook (results filed Oct 26, 2026)

• “Patient opportunity1 Patient population F Description Phase 1 Part Phase 1 Part Post-IO + TKI – Establish XmAb819 Monotherapy Post IO-TKI IV monotherapy Post-IO + TKI ~23.9K Ongoing End of Phase 1 meeting 1H 2027 A & B Status Expected Milestone or Readout U.S.”

Quoted word-for-word from the SEC 8-K results press release.

XNCR analyst estimates and revisions

XNCR options: expected move

Options price a move of about ±17.8% (±$5.28) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.9% on average.

30-day implied volatility 87.3% vs 64.5% realized over the last 30 trading days. Put/call ratio (volume) 0.32. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:49 UTC)

Technical Analysis (XNCR)

Nexqual's technical model rates XNCR "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 20:49 UTC.

Analyst Ratings (XNCR)

Wall Street analysts rate XNCR "Buy" based on 14 analysts, with a mean price target of USD 40.25 (range USD 21–70), per Nexqual as of October 29, 2026 at 20:49 UTC.

Earnings (XNCR)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:49 UTC.

Financials & Fundamentals (XNCR)

Source: Nexqual, October 29, 2026 at 20:49 UTC.

Financial Health Score (XNCR)

Nexqual rates Xencor, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:49 UTC.

Ownership (XNCR)

Source: Nexqual, October 29, 2026 at 20:49 UTC.

Leadership (XNCR)

Xencor, Inc. is led by Bassil I. Dahiyat, Co-Founder, CEO, President & Director, per Nexqual as of October 29, 2026 at 20:49 UTC.

Major Backers & Investors (XNCR)

Notable institutional backers of Xencor, Inc. include Primecap Management Company, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund, BVF Inc., according to Nexqual as of October 29, 2026 at 20:49 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:49 UTC.

From Xencor, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• In the United States, the FDA regulates drugs and biologic products under the Federal Food, Drug and Cosmetic Act (FDCA), its implementing regulations, and other laws including, in the case of biologics, the Public Health Service Act.
• Biologics require the submission of a Biologics License Application (BLA) to the FDA and approval of the BLA by the FDA before marketing in the United States.
• We seek to protect our proprietary XmAb technologies and XmAb drug candidates by filing and prosecuting patents in the United States and other jurisdictions.
• Where appropriate, we pursue the expansion and extension of patent coverage for our proprietary and partnered programs incorporating our XmAb technologies. * Alexion and Incyte are conducting additional Phase 3 studies in new indications.

Partnerships

• Master Services Agreement with Kapadi (formerly OncoBay Clinical, Inc.) In August 2023, we entered into a master services agreement with OncoBay Clinical, Inc., now known as Kapadi, for CROs services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).
• In August 2019, we entered into an agreement with Vir Bio pursuant to which we granted Vir Bio a non-exclusive license to our Xtend technology for two infectious disease targets.

Legal & Regulatory Risks (Item 1A, quoted)

• We may be required to reduce the scope of our intellectual property due to third-party intellectual property claims.
• The development and commercialization of biologic products is subject to extensive regulation, and we may not obtain regulatory approvals for any of our product candidates.
• Our business involves the controlled use of hazardous materials and as such we are subject to environmental and occupational safety laws. Continued compliance with these laws may incur substantial costs and failure to maintain compliance could result in liability for damages that may exceed our resources.
• New federal and state income tax legislation may affect our current and future income tax liabilities.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:49 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt